Bli medlem
Bli medlem

Du är här


Recipharm AB: Recipharm prices its initial public offering at SEK 78 per share - trading on NASDAQ OMX Stockholm commences today, April 3 2014


Recipharm AB (publ) ("Recipharm" or the "Company"), a leading CDMO
(Contract Development and Manufacturing Organisation) in the
pharmaceutical industry, today announces the outcome of the initial
public offering of its shares and listing on NASDAQ OMX Stockholm
(the "Offering").

The Offering attracted strong interest among Swedish and international
institutional investors as well as Swedish retail investors. The
Offering was substantially oversubscribed.

The Offering in brief:

· The final price in the Offering has been set at SEK 78 per share
of series B, corresponding to a market value of all shares issued by
Recipharm of SEK 2,794 million.

· Recipharm receives approximately SEK 815 million in gross

· To cover potential over-allotment in connection with the Offering,
Lars Backsell and Thomas Eldered[1] (the "Principal Shareholders")
have undertaken, at the request of the Joint Lead Managers Carnegie
Investment Bank AB (publ) and Skandinaviska Enskilda Banken AB
(publ), to sell additional existing shares corresponding to up to 15
per cent of the number of shares of series B comprised by the
Offering (the "Over-Allotment Option")[2], equal to not more than
2,517,884 shares of series B, representing approximately 7 per cent
of the total number of shares in the Company.

· The Offering comprises 19,303,779 shares of series B,
corresponding to approximately 54 per cent of the total number of
shares in the Company if the Over-Allotment Option is exercised in

· The total value of the Offering amounts to SEK 1,506 million,
assuming that the Over-Allotment Option is exercised in full.

· Trading in Recipharm's shares of series B on NASDAQ OMX Stockholm
commences today, 3 April 2014 under the symbol "RECI B"[3].

Thomas Eldered, CEO, comments:
"It is very encouraging that the interest from both international
institutional investors and retail investors in Sweden has been so
strong. We see this as a confirmation of the strong faith in
Recipharm's chances to grow and successfully exploit the business
opportunities that the market offers a first class CDMO in the
pharmaceutical industry."

Lars Backsell, CoB, comments:
"From being a small entrepreneurial company created by two enthusiasts
almost 20 years ago, Recipharm has grown up and developed into a
large listed company with approximately 5,000 new shareholders.
Recipharm enters a new phase, but we as majority owners will together
with our new shareholders continue to develop the company with the
same commitment and dedication, now in a listed environment."

Following completion of the Offering and assuming that the
Over-Allotment Option is exercised in full, the Principal
Shareholders will remain the largest owners with approximately 46 per
cent of the shares and 87 per cent of the votes in Recipharm[4]
Recipharm will have approximately 5,000 shareholders.

Carnegie Investment Bank AB (publ) and Skandinaviska Enskilda Banken
AB (publ) are acting as Joint Lead Managers and Joint Bookrunners in
connection with the Offering. Swedbank AB (publ) is acting as Co-lead

For further information please visit or contact:

Thomas Eldered, CEO,, telephone: +46 8
602 52 10

Björn Westberg, CFO,, telephone: +46 8
602 46 20

This information is in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the
regulations of NASDAQ OMX Stockholm. This information was submitted
for publication on 3 April, 2014, at 07.30 CET.

Important information

This announcement is not an offer to sell or a solicitation of any
offer to buy any securities issued by Recipharm in any jurisdiction
where such offer or sale would be unlawful.

In any EEA Member State, other than Sweden, that has implemented
Directive 2003/71/EC as amended (together with any applicable
implementing measures in any member State, the "Prospectus
Directive"), this communication is only addressed to and is only
directed at qualified investors in that Member State within the
meaning of the Prospectus Directive.

Any securities referred to herein have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the
"Securities Act"), and may not be offered or sold in the United
States absent registration or an exemption from registration under
the Securities Act. There is no intention to register any securities
referred to herein in the United States or to make a public offering
of the securities in the United States. Any securities sold in the
United States will be sold only to qualified institutional buyers (as
defined in Rule 144A under the Securities Act) pursuant to Rule 144A.

In the United Kingdom, this document and any other materials in
relation to the securities described herein is only being distributed
to, and is only directed at, and any investment or investment
activity to which this document relates is available only to, and
will be engaged in only with, "qualified investors" (as defined in
section 86(7) of the Financial Services and Markets Act 2000) and who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment
professionals" in Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high
net worth entities falling within Article 49(2)(a) to (d) of the
Order (all such persons together being referred to as "relevant
persons"). Persons who are not relevant persons should not take any
action on the basis of this document and should not act or rely on

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden
employing some 1,500 employees. Recipharm offers manufacturing
services of pharmaceuticals in various dosage forms, production of
clinical trial material and pharmaceutical product development.
Recipharm currently manufactures more than 200 different products to
both Big Pharma and smaller research- and development companies.
Recipharm's turnover is approximately SEK 2.1 billion and the Company
operates development and manufacturing facilities in Sweden, France,
the UK, Germany and Spain and is headquartered near Stockholm.

For more information on Recipharm and our services, please visit


Through the company B&E Participation AB.

The Over-Allotment Option can be exercised, on one or more occasions,
in whole or in part, by the Joint Lead Managers, being responsible
for any stabilisation in connection with the Offering during a period
of 30 calendar days from and including the first day of trading of
the shares at NASDAQ OMX Stockholm.

Trading in Recipharm's shares on NASDAQ OMX Stockholm is up to and
including 7 April, 2014 is conditional upon the terms in the Offering
being fulfilled.

Full conversion of the Company's convertible bond programme, which
falls due for repayment on 6 April 2014 if conversion is not
requested by 5 April 2014, corresponds to a dilution of 3.77 per cent
of the shares and 0.93 per cent of the votes. As per 31 December,
2013 the outstanding loan amount was SEK 39.0 million.

Recipharm AB (publ)
Corporate identity number 556498-4825
Street address Lagervägen 7, Jordbro Telephone +46 8 602 52 00
Postal address Lagervägen 7, SE-136 50 Jordbro Fax +46 8 81 87 03


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.